A half-life extended monoclonal antibody targeting kallikreins 5 and 7, in Phase 2 proof-of-concept trial for atopic dermatitis.

Triveni Bio develops first-in-class antibody therapeutics for immunological and inflammatory disorders using a genetics-informed approach.
Triveni Bio is a clinical-stage biotechnology company developing novel antibody therapeutics for immunological and inflammatory (I&I) disorders. It combines a Mendelian genetics-informed precision medicine approach with advanced antibody engineering to identify targets and build functional antibodies. Its pipeline includes TRIV-509, a dual kallikreins 5 and 7 inhibitor in Phase 2 for atopic dermatitis; TRIV-573, a bispecific antibody targeting KLK5/7 and interleukin 13; and TRIV-920, a first-in-class dual trypsin 1 and 2 inhibitor in preclinical development for pancreatitis.
Founded in 2023 through the merger of Amagma Therapeutics and Modify Therapeutics, Triveni Bio is headquartered in Watertown, Massachusetts. The company has raised over $272 million across three funding rounds, including a $92 million Series A, a $115 million Series B, and a $65 million Series C co-led by Ascenta Capital and Janus Henderson Investors in June 2026. Triveni Bio is led by CEO Vishal Patel, PhD, Chief Medical Officer Bhaskar Srivastava, MD, PhD, and Chief Scientific Officer Jennifer Dovey, PhD.
Companies similar to Triveni Bio include Eli Lilly and Company, Sanofi, Infinimmune and Dren Bio.
Triveni Bio was founded in 2023.
Triveni Bio's headquarters is located in Watertown, MA, US.
Triveni Bio's most recent funding round was for $65M (USD) in June 2026.
As of Jun 17, 2026, Triveni Bio has raised a total of $272M (USD).
Triveni Bio has 6 employees as of Feb 4, 2024.
Infinimmune
infinimmune.com